SGLT2 inhibitors promote hepatoprotection through Akkermansia-enriched remodeling, while thiazolidinediones and DPP-4 inhibitors have neutral or harmful effects on hepatic steatosis (Zhang S. et al., 2024). This evidence concerns the gene DPP4 and Hepatic steatosis.